Abstract 850P
Background
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults. The origin can be found in chromosomal translocations as well as in accumulated mutations in genes involved in hematopoietic proliferation and differentiation. Despite being considered a heterogeneous malignancy, AML possesses many genetic aberrations, including the overexpression of MYC and the downregulation of PP2A, both essential regulators of cell proliferation, apoptosis, and differentiation, and they, directly and indirectly, regulate each other’s activity. We have generated a zebrafish model of MYC-driven AML to rapidly test the effects of different drugs in tumor development.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we checked the expansion of neutrophils in whole larvae and the colonization of the adult hematopoietic organ. We investigated the effects of chemical manipulation of PP2A activity on neutrophil expansion and on MYC phosphorylation and degradation. Single-cell RNA sequencing analysis has been performed to shed light into the mechanisms of PP2A/proteasomal-mediated degradation of oncogenic MYC in AML.
Results
In vivo imaging of whole larvae revealed a robust expansion of neutrophils in zebrafish larvae which expressed MYC from 3 to 8 days post-fertilization (dpf). Surprisingly, the neutrophil number gradually returned to normal levels from 10 dpf onwards, coinciding with degradation of MYC. Pharmacological inhibition of the proteasome resulted in the stabilization of MYC protein and further expansion of transformed neutrophils. Similarly, inhibition of PP2A phenocopied the effects of proteasome inhibition. Otherwise, pharmacological activation of PP2A prevented neutrophil expansion and increased phosphorylation of S62 and T58 of MYC, suggesting a critical role PP2A in MYC proteasomal degradation.
Conclusions
Our results show that PP2A critically regulates MYC degradation in neutrophils preventing their oncogenic transformation. In addition, the zebrafish model of AML is a unique tool for chemical screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18